Objectives: An association between cystic fibrosis transmembrane regulator (CFTR) gene mutations and infertility may occur. This study investigated the frequency of mutations in the CFTR gene, in a group of consecutive patients candidate for assisted reproductive techniques with the aim of identify subjects carriers of the most severe ones. Methods: We screened 11208 healthy subjects (5943 females and 5265 males) for 56 CFTR gene mutations and IVS8-poliT polymorphism utilizing the CFTR INNO-LiPA Amplification kit including both general and Italian regional strips. The frequency of mutations were separately calculated and the Chi-square test was used for comparisons. Conclusions: CFTR mutations were detected in 6.2% of the patients, a percentage similar to that reported in the general population. The most common mutation was DF508/N observed in 0.9% of patients. No difference in the gender distribution was evidenced. In the large group of patients analyzed 87.7% were wt, 11.8% carrier of one mutation, and interestingly 0.5% compound heterozygous. Our data support the relevance of an accurate determination of mutations in the CFTR gene in order to inform the couple of their carrier risk and the possibility on having affected child. Moreover, our findings highlight the potential of genetic screening as a tool to identify possible compound heterozygous subjects without CF-like symptoms. Acknowledgements: The authors wish to thanks the directors and their staff of the following assisted reproduction centres, for their greatly appreciated collaboration:
Background: Newborn screening for cystic fibrosis (CF), based on immunoreactive trypsinogen (IRT) and 7 most common CFTR mutations, was introduced in Switzerland on January 1 st , 2011. The suggested IRT value for the 99 th percentile from the literature was 60 ng/ml. In a test run in December 2010, the corresponding IRT value for the 99 th percentile turned out to be lower (45 ng/ml). One aim of this pilot study was to find out if this cut-off is too low and resulting in unnecessary 2 nd IRT measurements if no CFTR mutations were found. Methods: We evaluated the IRT cut-off, recall rate, the number of children referred to a CF centre, and compared it to IRT values of the confirmed diagnosis. All children referred to a CF centre had an additional IRT measurement when sweat testing was performed. Results: In the first 4 months, 27,297 IRT tests were performed, 0.92% of them (251/27,297) were above 45 ng/ml, and DNA screening was performed. In 211 children, a 2 nd IRT measurement was necessary (recall rate 0.77%). 40 children were referred to a CF centre (referral rate 15.9%) and the positive predictive value was 20% (8/40). No child with CF had an IRT value <50 ng/ml. All 15 children with initial IRT between 45 and 60 ng/ml and no CFTR mutations had a normal 2 nd IRT test. After changing the IRT cut-off, the recall rate decreased by 45%: In the further 8 months, only 228 children needed an 2 nd IRT test and 45 were referred to a CF centre for sweat testing, and only 4 out of them had twice an elevated IRT value but no CFTR mutation. Conclusions: The change of the IRT cut-off from 45 to 50 ng/ml (99.5 th percentile) resulted in less recalls without losing diagnostic accuracy.
Pilot newborn screening program for cystic fibrosis in Uruguay:
IRT-PAP Objectives: Newborn screening (NBS) for cystic fibrosis (CF) has been implemented in the form of nationwide Immunoreactive trypsinogen (IRT) / DNA/IRT scheme in the Czech Republic since autumn 2009. Total number of 84 485 children were born and examined for CF in the Moravian part of the Czech Republic in two years period. The aim was to evaluate incidence of CF and frequency of pathologic alelas in CFTR gene. Methods: Dry blood spot was checked for IRT. Levels above 65 ng/ml were sent to molecular analyses, where they were screened for 50 mutations. Children with only one mutation were invited for sweat test. Results: Elevated IRT was detected in 953 cases out of the total 84 585. Thirteen CF children were diagnosed. All of them were symptomatic already in 6 weeks. After adequate therapy, all of them are in very good status. Four children were heterozygous for two mutations but with sweat test under 30 mmol/l and healthy. We detected combination of F508del/R117H twice, and both F508del/D1152 and N1303K/D1152H once. Another 78 children with one mutation were checked, all were healthy. During the last two years we diagnosed one CF in 6 020 newborns. There were only 14 types of pathologic alelas. F508del was the most frequent mutation in 58% followed by D1152H and R117H. One baby passed NBS undetected with IRT 61 ng/ml respective 40 ng/ml and was diagnosed as CF homozygous F508del because of clinical symptoms later at the age of 8 weeks.
Conclusions:
We can confirm that NBS is a valuable method; all CF children diagnosed at early age are doing well. In symptomatic babies with negative NBS it is necessary to perform sweat test as well. Failure of NBS is possible.
